SCHEMBL1287573

SCHEMBL1287573

CCc1oc2ccccc2c1C(=O)c1cc(C)c(O)c(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 7/20 1.00
CYP2C9 P11712 5/20 1.00
EYA3 Q99504 7/20 0.76
TTR P02766 6/20 0.76
MEN1 O00255 2/20 0.76
ABCB11 O95342 2/20 0.76
LMNA P02545 2/20 0.76
PGR P06401 2/20 0.76
ADRA2A P08913 2/20 0.76
TBXA2R P21731 2/20 0.76
OPRM1 P35372 2/20 0.76
SLC6A3 Q01959 2/20 0.76
KMT2A Q03164 2/20 0.76
BIRC5 O15392 1/20 0.76
HTR1A P08908 1/20 0.76
DRD1 P21728 1/20 0.76
PTGS1 P23219 1/20 0.76
SLC6A2 P23975 1/20 0.76
PDE4A P27815 1/20 0.76
ADORA1 P30542 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19235987 0.91 CYP2C19 (0.86) CYP2C19CYP2C9EYA3TTRMEN1
SCHEMBL28104860 0.88 CYP2C19 (0.78) CYP2C19CYP2C9EYA3TTRMEN1
SCHEMBL11847986 0.87 EYA3 (0.78) CYP2C19CYP2C9EYA3TTRMEN1
SCHEMBL9444916 0.87 CYP2C19 (0.77) CYP2C19CYP2C9EYA3TTRMEN1
Benziodarone SCHEMBL31326233 0.86 EYA3 (1.00) CYP2C19CYP2C9EYA3TTRMEN1
Benziodarone SCHEMBL308541 0.86 EYA3 (1.00) CYP2C19CYP2C9EYA3TTRMEN1
SCHEMBL1287556 0.86 CYP2C19 (1.00) CYP2C19CYP2C9EYA3TTRMEN1
Benzbromarone SCHEMBL19205474 0.85 SLC22A12 (1.00) CYP2C19CYP2C9EYA3TTRMEN1
Benzbromarone SCHEMBL29361528 0.85 SLC22A12 (1.00) CYP2C19CYP2C9EYA3TTRMEN1
SCHEMBL1287534 0.85 CYP2C19 (0.74) CYP2C19CYP2C9EYA3TTRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023242107-A1 NOVEL RAS INHIBITORS KHR Biotec GmbH (DE) 2023-12-21 WO disclosed
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action J-PHARMA CO., LTD. (JP) 2018-06-26 US disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2013-08-29 US disclosed
WO-2012048058-A2 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2012-04-12 WO disclosed
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 US disclosed
US-5274000-A 2-alkyl-3-carboxyalkylene or amidoalkyleneoxy-1,4-phenylene KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1993-12-28 US disclosed
US-5175184-A Diuretics KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1992-12-29 US disclosed
US-5004750-A Diuretics KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1991-04-02 US disclosed
US-4797415-A DIURETICS FOR GOUT KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1989-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 CYP2C19 2141/4885CYP2C9 1450/4885EYA3 3536/4885
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action SLCO2B1, SLCO2A1, SLC10A6 CYP2C19 269/4885CYP2C9 203/4885EYA3 4828/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 CYP2C19 2160/4885CYP2C9 1418/4885EYA3 3483/4885
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION SLCO2B1, SLCO2A1, SLC10A6 CYP2C19 269/4885CYP2C9 203/4885EYA3 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.